Huang, Yunchao
Kunming Medical University
3 papers on CoChatORCID 0000-0002-9840-8199
Most cited papers
- Verified
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 1,978
- Verified
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., et al. (2016) · Annals of Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 194
- Verified
Integrated multi-omics analysis for lung adenocarcinoma in Xuanwei, China
Jiang, B., Yang, J., He, R., Wang, D., Huang, Y., Zhao, G., Ning, M., Zeng, T., & Li, G. (2023) · Aging
Lung Cancer Research StudiesLung Cancer Treatments and Mutations
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free